• Xinyu Hu, Lulu Li, Yuanying Song, and Yun Lu.
• Chengdu University of Traditional Chinese Medicine, School of Clinical Medicine.
• Medicine (Baltimore). 2021 Jan 8; 100 (1): e24131e24131.

BackgroundPrevious review indicate that the effect of traditional Chinese medicines (TCM) on pulmonary heart disease (PHD) remains uncertainty. Therefore, we designed this study to systematically evaluate the effectiveness and safety of TCM in the treatment of PHD.MethodsNine online databases will be searched from inception to October 01, 2021, and we will not restrict the language on included trials. Randomized controlled trials that included patients with PHD receiving TCM therapy vs a control group will be included. Two of us will perform independently the selection of studies, risk of bias assessment, and data extraction. The RevMan V.5.2 software with fixed effects model or random effects model will be used to syntheses the data, according to the heterogeneity test to conduct the data synthesis. The dichotomous data and the continuous data will be presented with risk ratios with 95% confidence intervals and weighted mean differences or standardized mean differences with 95% confidence intervals. And we will use the Grading of Recommendations Assessment, Development, and Evaluation system to evaluate the evidence quality.ResultThis study will assess effects and safety for TCM on PHD.ConclusionThe conclusion of this study will provide evidence to prove the safety and effectiveness of TCM on PHD.Trial Registration NumberINPLASY2020120024.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…